Quick Answer
NextCure, Inc. reported Total Revenue of $22.38 million for fiscal year 2020.
NextCure, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $22.38M +252.6% |
| Revenue (ASC 606) | — | — | — | — | — | $22.38M +252.6% |
| Net Income | -$55.84M -0.3% |
-$55.65M +11.3% |
-$62.72M +16.1% |
-$74.73M -7.7% |
-$69.39M -89.6% |
-$36.60M -8.5% |
| Diluted EPS | -$19.65 +17.7% |
-$23.88 -961.3% |
-$2.25 +16.4% |
-$2.69 -7.2% |
-$2.51 -88.7% |
-$1.33 |
| Total Assets | $50.18M -37.9% |
$80.86M -36.8% |
$128.04M -30.5% |
$184.16M -24.0% |
$242.39M -21.0% |
$306.64M -13.9% |
| Cash and Equivalents | $25.98M -6.3% |
$27.73M +111.9% |
$13.08M -50.9% |
$26.63M +115.9% |
$12.34M -62.4% |
$32.77M -3.9% |
| Long-Term Debt | — | — | — | — | — | $1.81M -45.8% |
| Stockholders Equity | $34.94M -46.6% |
$65.47M -42.8% |
$114.42M -31.7% |
$167.53M -28.2% |
$233.39M -20.5% |
$293.72M -8.6% |
| R&D Expense | $44.92M +8.3% |
$41.49M -13.4% |
$47.93M -11.6% |
$54.20M +8.0% |
$50.19M +7.8% |
$46.55M +36.1% |
| Operating Income | -$57.62M +3.6% |
-$59.75M +11.7% |
-$67.64M +10.9% |
-$75.91M -7.3% |
-$70.77M -71.7% |
-$41.23M -10.0% |
| Shares Outstanding | 3.51M +50.2% |
2.33M -91.6% |
27.90M +0.5% |
27.77M +0.3% |
27.68M +0.4% |
27.57M +77.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2020 | $22.38M | +1549.1% | +1313.6% |
| Revenue (ASC 606) | March 31, 2020 | $22.38M | +1549.1% | +1313.6% |
| Net Income | September 30, 2025 | -$8.62M | +25.3% | +67.8% |
| Diluted EPS | September 30, 2025 | -$3.22 | +34.9% | +71.5% |
| Total Assets | September 30, 2025 | $39.61M | -56.2% | -16.9% |
| Cash and Equivalents | September 30, 2025 | $7.32M | -73.6% | +49.7% |
| Long-Term Debt | June 30, 2021 | $972.0K | -63.2% | -30.0% |
| Stockholders Equity | September 30, 2025 | $23.65M | -68.7% | -20.2% |
| R&D Expense | September 30, 2025 | $6.14M | -30.0% | -74.5% |
| Operating Income | September 30, 2025 | -$8.95M | +28.4% | +67.2% |
| Shares Outstanding | September 30, 2025 | 2.68M | -90.4% | +14.5% |
- NextCure, Inc. reported Total Revenue of $22.38 million for fiscal year 2020.
- NextCure, Inc. showed an increase of +252.6% in Total Revenue compared to the prior fiscal year.
- NextCure, Inc. reported Revenue (ASC 606) of $22.38 million for fiscal year 2020.
- NextCure, Inc. showed an increase of +252.6% in Revenue (ASC 606) compared to the prior fiscal year.
- NextCure, Inc. reported Net Income of -$55.84 million for fiscal year 2025.
- NextCure, Inc. showed a decrease of -0.3% in Net Income compared to the prior fiscal year.
- NextCure, Inc. reported Diluted EPS of $19.65 per share (loss) for fiscal year 2025.
- NextCure, Inc. showed an increase of +17.7% in Diluted EPS compared to the prior fiscal year.
- NextCure, Inc. reported Total Assets of $50.18 million for fiscal year 2025.
- NextCure, Inc. showed a decrease of -37.9% in Total Assets compared to the prior fiscal year.
- NextCure, Inc. reported Cash and Equivalents of $25.98 million for fiscal year 2025.
- NextCure, Inc. showed a decrease of -6.3% in Cash and Equivalents compared to the prior fiscal year.
- NextCure, Inc. reported Long-Term Debt of $1.81 million for fiscal year 2020.
- NextCure, Inc. showed a decrease of -45.8% in Long-Term Debt compared to the prior fiscal year.
- NextCure, Inc. reported Stockholders Equity of $34.94 million for fiscal year 2025.
- NextCure, Inc. showed a decrease of -46.6% in Stockholders Equity compared to the prior fiscal year.
- NextCure, Inc. reported R&D Expense of $44.92 million for fiscal year 2025.
- NextCure, Inc. showed an increase of +8.3% in R&D Expense compared to the prior fiscal year.
- NextCure, Inc. reported Operating Income of -$57.62 million for fiscal year 2025.
- NextCure, Inc. showed an increase of +3.6% in Operating Income compared to the prior fiscal year.
- NextCure, Inc. reported Shares Outstanding of 3.51 million shares for fiscal year 2025.
- NextCure, Inc. showed an increase of +50.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: